Pre-close Trading Update

Quantum Pharma Plc

("Quantum", the "Company" or the "Group")

Pre-close Trading Update

Quantum Pharma Plc (AIM: QP.), a growing manufacturer, supplier and service provider to the niche pharmaceutical sector, today announces its pre-close trading update for the financial year ended 31 January 2015.

The Board is pleased to announce that Quantum has made progress across all areas of its business in the last financial year, with strong performance in the final quarter, and the Board expects adjusted EBITDA and adjusted profit before tax for the full year to be comfortably ahead of market expectations.

The Group's core business, Quantum Pharmaceutical, continued to increase its customer base across the unlicensed medicine and Special Obtains market, maintaining its position as the clear market leader in this sector. As announced on 29 December 2014, Quantum Pharmaceutical secured an exclusive three year supply agreement with Bestway Panacea Healthcare Limited (whose 774 stores currently trade under the Co-operative Pharmacy name).

Colonis, the specialist pharmaceutical product development business, reached a significant milestone by launching its first licensed medicine, Aviticol 20,000 IU capsules, having received a licence on 18 December 2014. Colonis continues to develop its pipeline of potential licensed medicines and has now submitted a further six dossiers to the MHRA, which are progressing through the licensing process.

U L Medicines, Biodose and Quantum Aseptics Services continue to develop in line with management's expectations and all enjoyed record final quarters.

Quantum will announce its Preliminary Results for the year ended 31 January 2015 in May 2015.

Andrew Scaife, Chief Executive Officer of Quantum Pharma Plc, said: "This has been a transformational year for Quantum with good progress made across all areas of the Group and Colonis reaching a very significant milestone with the launch of its first licensed medicine. We were delighted with the support we received from our new shareholders on the successful IPO in December and we look to the future with confidence."

- Ends -

For further information:

Media enquiries:

Notes to Editors

Quantum Pharma is a growing manufacturer, supplier and service provider to the wholesale and retail pharmacy, hospital, homecare and care home markets. Based in a purpose-built facility in Burnopfield, County Durham, the Group manufactures and sources non-standard pharmaceutical products. Formed in 2004, Quantum has grown significantly in recent years (both organically and by acquisition) and now employs over 320 people. The Group operates through five business units.

Quantum Pharmaceutical, the Group's core business, manufactures and supplies Specials and Special Obtains to the majority of the large retail pharmacy chains and pharmaceutical wholesalers in the UK, hospitals, independent pharmacies and dispensing doctors. Specials and Special Obtains are medicines and medicinal products that are difficult for pharmacies to source from wholesale pharmacy suppliers. Quantum has a product range of over 22,000 Special and Special Obtain products. It regularly services around 6,500 pharmacies and over 240 hospital accounts across the UK.

U L Medicines ("ULM") is a supplier of unlicensed imports (over 450 imported medicines), over 100 batch made Specials and bespoke Specials with a focus on the hospital market. ULM has a diverse customer base and supplies over 240 hospital accounts, as well as wholesalers and retail pharmacies in the UK and wholesalers overseas.

Colonis is a specialist pharmaceutical product development business, which focuses on achieving the relevant regulated status for medicines and medical devices. The development programme is currently working on a significant pipeline of products across 15 therapeutic areas.

Biodose isa patent protected medicine delivery system ("MDS") which consists of a tray, 28 medication pods and a seal, which is used to manage pre-prepared medication regimes for patients. These assist with patient specific medicine administration and adherence to medication regimes. The Biodose system is currently sold to around 175 pharmacy customers, through whom around 50,000 care home residents use Biodose.

Quantum Aseptics' facility at Burnopfield became operational in April 2013 after receiving an MHRA aseptic special manufacturing licence. This facility, which the Director's believe to be is one of the most advanced aseptics units in the UK, provides Quantum Aseptics (a division of Quantum Pharmaceutical) with the ability to aseptically prepare and supply intravenous dosage form aseptic products, whilst complementing the existing core business product offering by providing the ability to prepare these sterile Specials for the Group's other business units and third parties.

For further information, please visit www.quantumpharmaplc.com.